Monument Capital Management acquired a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 28,887 shares of the financial services provider’s stock, valued at approximately $6,081,000. iShares Biotechnology ETF comprises about 1.3% of Monument Capital Management’s portfolio, making the stock its 14th biggest position.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. IFP Advisors Inc grew its stake in shares of iShares Biotechnology ETF by 39.3% during the second quarter. IFP Advisors Inc now owns 49,988 shares of the financial services provider’s stock valued at $9,507,000 after buying an additional 14,115 shares during the last quarter. Security National Bank of Sioux City Iowa IA increased its stake in iShares Biotechnology ETF by 31.8% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 12,187 shares of the financial services provider’s stock worth $2,318,000 after purchasing an additional 2,939 shares during the period. Kestra Advisory Services LLC lifted its position in shares of iShares Biotechnology ETF by 12.2% during the first quarter. Kestra Advisory Services LLC now owns 47,461 shares of the financial services provider’s stock worth $8,014,000 after purchasing an additional 5,155 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of iShares Biotechnology ETF by 64.0% during the second quarter. The Manufacturers Life Insurance Company now owns 101,838 shares of the financial services provider’s stock valued at $19,369,000 after purchasing an additional 39,760 shares during the period. Finally, Southern Capital Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 20.7% in the first quarter. Southern Capital Advisors LLC now owns 28,186 shares of the financial services provider’s stock worth $4,759,000 after purchasing an additional 4,833 shares during the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.
iShares Biotechnology ETF Stock Down 1.4%
NASDAQ:IBB opened at $200.48 on Friday. The company has a 50-day moving average of $205.40 and a 200 day moving average of $186.32. iShares Biotechnology ETF has a 1-year low of $149.09 and a 1-year high of $217.12.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Applied Digital’s Hidden Moat Could Unlock Massive Upside
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
